BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Biotech catalysts in 2025-03

185 industry Phase 2/3 trial readout(s) and 42 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.

← 2025-02 | 2025-04 →

FDA decision events

DateEventStatusCompanyDrugSource
2025-03-03FDA approvalapprovedBEIGENETEVIMBRAApproved 2025-03-03: TEVIMBRA (BLA761380 ORIG1)
2025-03-05FDA approvalapprovedARS PHARMS OPERATIONNEFFYApproved 2025-03-05: NEFFY (NDA214697 SUPPL1)
2025-03-06FDA approvalapprovedSCPHARMACEUTICALSFUROSCIX FUROSCIX READYFLOWApproved 2025-03-06: FUROSCIX; FUROSCIX READYFLOW (AUTOINJECTOR) (NDA209988 SUPPL3)
2025-03-07FDA approvalapprovedBOEHRINGER INGELHEIMSYNJARDYApproved 2025-03-07: SYNJARDY (NDA206111 SUPPL45)
2025-03-07FDA approvalapprovedNOVARTIS NVSMEKINISTApproved 2025-03-07: MEKINIST (NDA217513 SUPPL5)
2025-03-07FDA approvalapprovedNOVARTIS NVSTAFINLARApproved 2025-03-07: TAFINLAR (NDA217514 SUPPL6)
2025-03-07FDA approvalapprovedNOVARTIS NVSTAFINLARApproved 2025-03-07: TAFINLAR (NDA202806 SUPPL33)
2025-03-07FDA approvalapprovedCELLTRION INCOMLYCLOApproved 2025-03-07: OMLYCLO (BLA761399 ORIG1)
2025-03-07FDA approvalapprovedBOEHRINGER INGELHEIMSYNJARDY XRApproved 2025-03-07: SYNJARDY XR (NDA208658 SUPPL32)
2025-03-07FDA approvalapprovedNOVARTIS NVSMEKINISTApproved 2025-03-07: MEKINIST (NDA204114 SUPPL34)
2025-03-10Complete response lettercomplete responseLaurus Generics, Inc.CRL 2025-03-10: Laurus Generics, Inc. NDA 217719
2025-03-11Complete response lettercomplete responseSeikagaku CorporationinjectionCRL 2025-03-11: Seikagaku Corporation BLA 761393 (injection)
2025-03-12FDA approvalapprovedARRAY BIOPHARMA INC ADBRAFTOVIApproved 2025-03-12: BRAFTOVI (NDA210496 SUPPL18)
2025-03-12FDA approvalapprovedARRAY BIOPHARMA INC ADMEKTOVIApproved 2025-03-12: MEKTOVI (NDA210498 SUPPL11)
2025-03-13Complete response lettercomplete responseAccord BioPharma Inc.CRL 2025-03-13: Accord BioPharma Inc. BLA 761424
2025-03-13FDA approvalapprovedSCIENTURE SCNXARBLIApproved 2025-03-13: ARBLI (NDA218772 ORIG1)
2025-03-13FDA approvalapprovedFRESENIUS KABI USAEPINEPHRINEApproved 2025-03-13: EPINEPHRINE (NDA215425 ORIG1)
2025-03-13FDA approvalapprovedIPSENSOHONOSApproved 2025-03-13: SOHONOS (NDA215559 SUPPL2)
2025-03-14FDA approvalapprovedFRESENIUS KABI USATYENNEApproved 2025-03-14: TYENNE (BLA761449 ORIG1)
2025-03-14FDA approvalapprovedXERIS XERSGVOKE HYPOPEN; GVOKE KIT; GVOKE PFS; GVOKE VIALDXApproved 2025-03-14: GVOKE HYPOPEN; GVOKE KIT; GVOKE PFS; GVOKE VIALDX (NDA212097 SUPPL12)
2025-03-17FDA approvalapprovedAMPHASTAR PHARMS INC AMPHBAQSIMIApproved 2025-03-17: BAQSIMI (NDA210134 SUPPL4)
2025-03-17FDA approvalapprovedPRM PHARMAHEMICLORApproved 2025-03-17: HEMICLOR (NDA218647 ORIG1)
2025-03-19FDA approvalapprovedMERCK SHARP DOHME MRKKEYTRUDAApproved 2025-03-19: KEYTRUDA (BLA125514 SUPPL170)
2025-03-20Complete response lettercomplete responseElevar Therapeutics, Inc.®® _ (rivoceranib) tabletsCRL 2025-03-20: Elevar Therapeutics, Inc. NDA 216586 (®® _ (rivoceranib) tablets)
2025-03-20Complete response lettercomplete responseJiangsu Hengrui Pharmaceuticals Co., Ltd JHPCYcamrelizumabCRL 2025-03-20: Jiangsu Hengrui Pharmaceuticals Co., Ltd BLA 761308 (camrelizumab)
2025-03-20FDA approvalapprovedNOVARTIS NVSFABHALTAApproved 2025-03-20: FABHALTA (NDA218276 SUPPL4)
2025-03-20FDA approvalapprovedALNYLAM PHARMS INC ALNYAMVUTTRAApproved 2025-03-20: AMVUTTRA (NDA215515 SUPPL6)
2025-03-20FDA approvalapprovedJANSSEN BIOTECHTREMFYAApproved 2025-03-20: TREMFYA (BLA761061 SUPPL24)
2025-03-20FDA approvalapprovedTELIX INNOVATIONS TLXGOZELLIXApproved 2025-03-20: GOZELLIX (NDA219592 ORIG1)
2025-03-21FDA approvalapprovedJANSSEN PRODSPREZCOBIXApproved 2025-03-21: PREZCOBIX (NDA205395 SUPPL28)
2025-03-25FDA approvalapprovedFRESENIUS KABI USA LLCBOMYNTRA; CONEXXENCEApproved 2025-03-25: BOMYNTRA; CONEXXENCE (BLA761398 ORIG1)
2025-03-25FDA approvalapprovedGLAXOSMITHKLINEBLUJEPAApproved 2025-03-25: BLUJEPA (NDA218230 ORIG1)
2025-03-26Complete response lettercomplete responseCELLTRION, Inc.CRL 2025-03-26: CELLTRION, Inc. BLA 761377
2025-03-26FDA approvalapprovedSOLENOVYKAT XRApproved 2025-03-26: VYKAT XR (NDA216665 ORIG1)
2025-03-26FDA approvalapprovedEXELIXIS INC EXELCABOMETYXApproved 2025-03-26: CABOMETYX (NDA208692 SUPPL17)
2025-03-27Complete response lettercomplete responseMilestone Pharmaceuticals USA, Inc. MISTetripamil nasal sprayCRL 2025-03-27: Milestone Pharmaceuticals USA, Inc. NDA 218571 (etripamil nasal spray)
2025-03-27FDA approvalapprovedNOVO NVORIVFLOZAApproved 2025-03-27: RIVFLOZA (NDA215842 SUPPL2)
2025-03-28FDA approvalapprovedOTSUKAABILIFY ASIMTUFIIApproved 2025-03-28: ABILIFY ASIMTUFII (NDA217006 SUPPL1)
2025-03-28FDA approvalapprovedNOVARTIS NVSPLUVICTOApproved 2025-03-28: PLUVICTO (NDA215833 SUPPL21)
2025-03-28FDA approvalapprovedGENZYME CORPQFITLIAApproved 2025-03-28: QFITLIA (NDA219019 ORIG1)
2025-03-28FDA approvalapprovedASTRAZENECA UK LTD AZNIMFINZIApproved 2025-03-28: IMFINZI (BLA761069 SUPPL50)
2025-03-28FDA approvalapprovedOTSUKA PHARM CO LTDABILIFY MAINTENA KITApproved 2025-03-28: ABILIFY MAINTENA KIT (NDA202971 SUPPL18)

Trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2025-03 est.P3SynCore Biotechnology Co., Ltd.NCT03002103 A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line TTriple-Negative Breast Cancersuspended420
2025-03 est.P2/P31Globe Health Institute LLCNCT03721744 A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic CancerMetastatic Pancreatic Cancerunknown336
2025-03 est.P2Imara, Inc.NCT04053803 An Extension Study of IMR-687 in Adult Patients With Sickle Cell AnemiaSickle Cell Diseaseactive not recruiting30
2025-03 est.P1/P2Philogen S.p.A.NCT04573192 A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First ProgressionGlioblastomaunknown142
2025-03 est.P3Instituto Grifols, S.A.NCT04636268 FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical ProphylaxisCongenital Afibrinogenemia; Hypofibrinogenemiawithdrawn
2025-03 est.P1/P2JeniVision, Inc.NCT04761705 Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular HypertensionOcular Hypertension; Open Angle Glaucomasuspended70
2025-03 est.P1/P2ImmVira Pharma Co. LtdNCT04780217 Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid TumorsSolid Tumor; Hepatocellular Carcinoma; Colorectal Cancer; NSCLC; Ovarian Cancer; Endometrial Cancerunknown42
2025-03 est.P3Beijing Mabworks Biotech Co., Ltd.NCT04834024 MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular LymphomaFollicular Lymphoma and Marginal Zone Lymphomaunknown168
2025-03 est.P3Romark Laboratories L.C.NCT05157269 Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe IllnessCOVID-19withdrawn
2025-03 est.P1/P223andMe, Inc.NCT05199272 A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid MalignanciesSolid Tumor; Clear Cell Renal Cell Carcinoma; Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primactive not recruiting141
2025-03 est.P1/P2Chipscreen Biosciences, Ltd.NCT05271292 Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.Small Cell Lung Cancer; Advanced Solid Malignant Tumorunknown36
2025-03 est.P2AmMax Bio, Inc.NCT05349760 A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary FibrosisIPFwithdrawn
2025-03 est.P3HugelNCT05801146 Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar LinesGlabellar Linesunknown272
2025-03 est.P2Immunoforge Co. Ltd.NCT05833711 Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory MyopathyDermatomyositis; Polymyositis; Idiopathic Inflammatory Myopathiesunknown39
2025-03 est.P1/P2AsclepiX Therapeutics, Inc.NCT05859776 Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-related Macular Degenerationunknown15
2025-03 est.P3Walvax Biotechnology Co., Ltd.NCT05934890 A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13Pneumococcal Disease, Invasiveunknown630
2025-03 est.P3Cellid Co., Ltd.NCT05993325 Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy VolunteersCOVID-19; Vaccinesactive not recruiting4000
2025-03 est.P3Mabscale, LLCNCT06005532 Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®Plaque Psoriasisunknown494
2025-03 est.P2Biocells (Beijing) Biotech Co.,LtdNCT06322394 BXOS110 Injection in the Treatment of Acute Ischaemic StrokeAcute Ischemic Strokeunknown300
2025-03 est.P2/P3Equipmed USA LLCNCT06602284 A Full Face Study to Evaluate the Efficacy of Dermapen 4™ Microneedling Device in Addition with MG-CLR Serum for Acne Treatment Over 12 Weeks.Acneunknown10
2025-03-01P3Pfizer PFENCT04607421 A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal CancerNeoplasmsactive not recruiting841
2025-03-01 est.P3Jiangsu Yahong Meditech Co., Ltd aka AsierisNCT04736394 A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride inNon-muscle Invasive Bladder Cancerunknown800
2025-03-01 est.P1/P2Erasca, Inc. ERASNCT05279859 A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic MalignanciesAcute Myeloid Leukemiawithdrawn
2025-03-01 est.P2/P3SUNHO(China)BioPharmaceutical CO., Ltd.NCT05673512 To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal CancerHER2 Gene Mutationunknown279
2025-03-01P3AbbVie ABBVNCT05861427 Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic MigraineMigrainecompleted524
2025-03-03P2ALX Oncology Inc. ALXONCT04675294 Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)Head and Neck Cancer; Head and Neck Squamous Cell Carcinomaactive not recruiting189
2025-03-03P2ALX Oncology Inc. ALXONCT04675333 Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)Head and Neck Cancer; Head and Neck Squamous Cell Carcinomaactive not recruiting172
2025-03-03P2Daiichi SankyoNCT05280470 Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Extensive-stage Small-cell Lung Canceractive not recruiting187
2025-03-03P3Jiangsu HengRui Medicine Co., Ltd.NCT05864014 Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.Chemotherapy-Induced Thrombocytopeniaactive not recruiting213
2025-03-03P2Kyoto Drug Discovery and Development Co., Ltd.NCT06178055 A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)Central Retinal Artery Occlusioncompleted17
2025-03-03P2Causeway TherapeuticsNCT06192927 Efficacy and Safety of TenoMiR in Lateral EpicondylitisTennis Elbowcompleted123
2025-03-04P1/P2Beijing Mabworks Biotech Co., Ltd.NCT05398653 A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous NephropathyPrimary Membranous Nephropathycompleted94
2025-03-04 est.P1/P2Shanghai Henlius BiotechNCT05641493 A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E MutationNon Small Cell Lung Cancerunknown49
2025-03-04P2Cognition Therapeutics CGTXNCT05893537 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).Age-Related Macular Degenerationterminated100
2025-03-04P3Sarepta Therapeutics, Inc. SRPTNCT06246513 A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular DystropLimb-girdle Muscular Dystrophyactive not recruiting17
2025-03-04P2Gilgamesh PharmaceuticalsNCT06309277 A Clinical Study to Evaluate of Single and Multiple Oral Doses of GM-1020 in Patients With MDDMajor Depressive Disordercompleted46
2025-03-04P3Serum Institute of India Pvt. Ltd.NCT06413121 Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPVDiptheria Immunization; Tetanus Immunization; Pertussis Immunization; Hepatitis B Immunization; Haemcompleted1557
2025-03-04P2Scholar Rock, Inc. SRRKNCT06445075 Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or ObeseOverweight and Obesitycompleted102
2025-03-04 est.P3Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.NCT06759857 FHND9041 Versus Afatinib for Non-small Cell Lung CancerNon Small Cell Lung Cancerenrolling by invitation350
2025-03-05P2Hoffmann-La RocheNCT04832854 A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in ParticipanNon-Small Cell Lung Cancer (NSCLC)terminated50
2025-03-05P3Merck Sharp & Dohme LLC MRKNCT05116189 Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).Ovarian Cancer; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasmsactive not recruiting643
2025-03-05P2Sanofi SNYNCT05326412 Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPDChronic Obstructive Pulmonary Diseasecompleted49
2025-03-05P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05472324 Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.Severe Asthmacompleted205
2025-03-05P2Pfizer PFENCT05492500 A Study of Ponsegromab in People With Heart FailureHeart Failureterminated455
2025-03-05P3Novo Nordisk A/S NVONCT05514535 A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People WitDiabetes Mellitus, Type 2; Obesitycompleted573
2025-03-05P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT05913336 A Study of Remimazolam Tosilate for Prolonged Sedation in the ICUSedation in the ICUcompleted24
2025-03-05P2Keros Therapeutics, Inc. KROSNCT05975905 A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAHPulmonary Arterial Hypertensionterminated113
2025-03-05P2Shandong Suncadia Medicine Co., Ltd.NCT06221059 Efficacy and Safety of HRS-1780 Tablets and Henagliflozin Proline Tablets in Patients With Chronic Kidney DiseaseChronic Kidney Diseasecompleted181
2025-03-05P2Sinotau Pharmaceutical GroupNCT07187895 Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary StenosisMyocardial Perfusion Imaging; Diagnostic Certainty; Stable Coronary Artery Diseaseterminated17
2025-03-05P2Novartis Pharmaceuticals NVSNCT07235033 Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)Uncomplicated Plasmodium Falciparum Malariacompleted60
2025-03-06P2/P3Magnus MedicalNCT03693105 The Effects of SAINT® Neuromodulation System on Explicit and Implicit Suicidal CognitionMajor Depressive Disorder; Major Depressive Episode; Suicidal Ideationterminated2
2025-03-06 est.P2Hoffmann-La RocheNCT04611776 A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After ComCarcinoma, Non-Small Cell Lungwithdrawn
2025-03-06P1/P2Affimed GmbHNCT05109442 Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing CancersAdvanced Solid Tumorterminated112
2025-03-06P3Bristol-Myers Squibb BMYNCT05582395 A Study of Mavacamten in Non-Obstructive Hypertrophic CardiomyopathyCardiomyopathy, Hypertrophicterminated580
2025-03-06P3Novartis Pharmaceuticals NVSNCT05678959 Long-term Extension Study of Ligelizumab in Food AllergyFood Allergyterminated163
2025-03-06P2iRenix Medical, Inc.NCT05747430 SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)Retinal Diseasecompleted155
2025-03-06P2Incyte Corporation INCYNCT05750823 A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital VitiligoNonsegmental Vitiligo With Genital Involvementcompleted49
2025-03-06P2Avistone Biotechnology Co., Ltd.NCT06015503 A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)NSCLC (Non-small Cell Lung Cancer)active not recruiting139
2025-03-06P2Tourmaline Bio, Inc., a Novartis CompanyNCT06362759 A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRPChronic Kidney Diseases; Chronic Kidney Insufficiency; Chronic Renal Diseases; Chronic Renal Insufficompleted143
2025-03-06P2/P3Magnus MedicalNCT06462820 SAINT for MDD in an Inpatient Setting Follow-onMajor Depressive Disorder; Major Depressive Episode; Suicidal Ideationterminated2
2025-03-06P2Kiniksa Pharmaceuticals International, plc KNSANCT06531395 A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's DiseaseSjögrens Diseaseterminated3
2025-03-07P1/P2Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)NCT04535193 Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic InnervationCardiovascular Diseasesactive not recruiting10
2025-03-07P2BioTissue Holdings, IncNCT05079035 Lyophilized and Micronized Particulate Human Amniotic and Umbilical Cord (TTAX03) for KL Grade 3-4 Knee OAKnee Osteoarthritis; Knee Pain Chronic; Knee Arthritiscompleted90
2025-03-07P2SOFIENCT05262855 Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal CarcinomaPDAC - Pancreatic Ductal Adenocarcinoma; FAPcompleted63
2025-03-07P3Bristol-Myers Squibb BMYNCT05644665 A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)Ulcerative Colitisterminated131
2025-03-07P1/P2Imunon IMNNNCT06283459 Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2SARS CoV 2 Infectioncompleted24
2025-03-07P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06901648 A Study of HS-20094 in Patients With T2DMType 2 Diabetescompleted275
2025-03-07P2Accro Bioscience (Suzhou) LimitedNCT06972888 A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque PsoriasisPlaque Psoriasiscompleted145
2025-03-08P2Technoderma Medicines Inc.NCT06363461 Study of TDM-180935 in Atopic Dermatitis PatientsAtopic Dermatitiscompleted24
2025-03-10P3Apnimed APMDNCT05813275 Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)OSAcompleted646
2025-03-10P3GlaxoSmithKlineNCT06597344 A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated UriUrinary Tract Infectionscompleted97
2025-03-11P3AGO Research GmbHNCT03353831 Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian CancerRecurrent Ovarian Carcinomacompleted574
2025-03-11P1/P2Astellas Pharma Global Development, Inc.NCT04240002 A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem DuAcute Myeloid Leukemia (AML); Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutationterminated9
2025-03-11P2/P3Galectin Therapeutics Inc. GALTNCT04365868 Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH CirrhosisPrevention of Esophageal Varices; NASH - Nonalcoholic Steatohepatitis; Cirrhosisterminated357
2025-03-11P1/P2Neurelis, Inc.NCT05076838 Pharmacokinetics Study of VALTOCO® in Pediatric Subjects With EpilepsyEpilepsycompleted36
2025-03-11P2Novartis Pharmaceuticals NVSNCT05432388 Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to PeanutsAllergy, Peanutcompleted76
2025-03-11P2Sanofi Pasteur, a Sanofi Company SNYNCT06251024 Study of a Respiratory Syncytial Virus Candidate Formulation in Adults Aged 60 Years and OlderRespiratory Syncytial Virus Infection; Healthy Volunteerscompleted4541
2025-03-12P2UCB Biopharma SRLNCT04718896 A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque PsoriasModerate to Severe Plaque Psoriasiscompleted41
2025-03-12P3AstraZeneca AZNNCT05113251 Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerBreast Neoplasms; Breast Cancer; HER2-positive Early Breast Canceractive not recruiting927
2025-03-13P2Arbutus Biopharma Corporation ABUSNCT04980482 Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionChronic Hepatitis bcompleted43
2025-03-13P1/P2Astria Therapeutics, Inc.NCT05695248 A Study of Navenibart (STAR-0215) in Participants With Hereditary AngioedemaHereditary Angioedemacompleted29
2025-03-13P3Sintetica SANCT05926258 Efficacy and Safety of Chloroprocaine 3% Gel and Oxybuprocaine 0.4% Eye Drops Anesthesia in Pediatric PopulationLocal Anestheticcompleted74
2025-03-13P2/P3BioNTech SE BNTXNCT05997290 A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy IndividualsSARS-CoV-2 Infection; COVID-19completed1051
2025-03-13P3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT06572449 Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With SchizophreniaSchizophreniacompleted173
2025-03-13P2Aclaris Therapeutics, Inc. ACRSNCT06585202 Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic DermatitisAtopic Dermatitiscompleted14
2025-03-14 est.P1/P2Shanghai EpimAb Biotherapeutics Co., Ltd.NCT03797391 A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid TumorsNeoplasms; Neoplasm Metastasis; Non-Small-Cell Lung Cancerunknown186
2025-03-14P2BayerNCT05254002 A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult ParticipaType 2 Diabetes Mellitus; Chronic Kidney Diseasecompleted1664
2025-03-14P2Incyte Biosciences International Sàrl INCYNCT05287113 Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/MetastatiHead and Neck Cancercompleted176
2025-03-14P2Jiangsu HengRui Medicine Co., Ltd.NCT05476900 A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.Autoimmune Hepatitiscompleted69
2025-03-14P2Regend TherapeuticsNCT06081621 A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosiscompleted23
2025-03-14 est.P2JemincareNCT06221241 Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic PainDiabetic Peripheral Neuropathic Painunknown220
2025-03-14P2EstetraNCT06308614 Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal WomenSexual Dysfunction, Physiologicalcompleted82
2025-03-14P3Huons Co., Ltd.NCT06388070 To Evaluate the Efficacy and Safety of HUC3-053 in Patients With Dry Eye SyndromeDry Eye Syndromescompleted297
2025-03-15 est.P2Energenesis Biomedical Co., Ltd.NCT04078555 A Study to Evaluate ENERGI-F703 GEL in Venous Leg UlcerVenous Leg Ulcerunknown80
2025-03-15 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT05261646 A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From ThChemotherapy-Induced Thrombocytopeniawithdrawn
2025-03-15 est.P2Tavotek BiotherapeuticsNCT06176040 A Study of TAVO101 in Atopic Dermatitis PatientsAtopic Dermatitisactive not recruiting20
2025-03-15 est.P3EMSNCT06237231 Efficacy and Safety of DIT112 in the Treatment of Moderate to Severe Pain After Dental Surgery for the Extraction of Impacted Third MolarsModerate Pain; Severe Painnot yet recruiting252
2025-03-15 est.P3EMSNCT06272409 Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.Allergic Rhinitisnot yet recruiting318
2025-03-15 est.P1/P2MGB PharmaNCT06672653 Tolerance and Effectiveness of C14 on HPV InfectionHPV-induced Cancers; HPV Infections; HIV; Cervical Cancers; Trial; C14; Monoterpenoid Zinc Tetra-ascnot yet recruiting66
2025-03-17P3AstraZeneca AZNNCT03737643 Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced OvariaAdvanced Ovarian Canceractive not recruiting1407
2025-03-17P3Otsuka Pharmaceutical Development & Commercialization, Inc.NCT05428033 A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)Attention Deficit/Hyperactivity Disordercompleted574
2025-03-17P2/P3Nicox Ophthalmics, Inc.NCT05938699 Aqueous Humor Dynamics of NCX 470 Ophthalmic SolutionOpen Angle Glaucomacompleted18
2025-03-18P1/P2Janssen Research & Development, LLCNCT04586426 A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple MyelomaMultiple Myelomaactive not recruiting228
2025-03-18P3UCB Biopharma SRLNCT05109234 A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or JuChildhood Absence Epilepsy; Juvenile Absence Epilepsycompleted84
2025-03-18P3Vascular Therapies, Inc.NCT05425056 A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula SurgeryComplication of Renal Dialysis; End Stage Renal Disease; End Stage Kidney Disease; ESRD; Chronic Kidcompleted136
2025-03-18P2Dompé Farmaceutici S.p.ANCT05496868 Add-on Reparixin in Adult Patients With ARDSAcute Respiratory Distress Syndrome, Adultcompleted66
2025-03-18P2UCB Biopharma SRLNCT05543252 An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's DiseaseParkinson's Diseaseterminated428
2025-03-18P3Rhythm Pharmaceuticals, Inc. RYTMNCT05774756 A Trial of Setmelanotide in Acquired Hypothalamic ObesityHypothalamic Obesityactive not recruiting143
2025-03-18P2NorthSea Therapeutics B.V.NCT05889156 Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With HypertriglyceridemiaHigh Triglyceridescompleted50
2025-03-19P3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyNCT05145413 A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaSchizophreniacompleted396
2025-03-19P1/P2BioAtla, Inc. BCABNCT05180799 A Phase 1/2 Study of BA3071 in Patients With Solid TumorsNSCLC; Melanomaunknown320
2025-03-19P1/P2Staidson (Beijing) Biopharmaceuticals Co., LtdNCT05197842 Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated VasculitisANCA-associated Vasculitiscompleted93
2025-03-19P2/P3IpsenNCT05769582 Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant RecipientsBK Viremia; BKV DNAemiacompleted95
2025-03-19P3Materia Medica HoldingNCT06263881 Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired PneumoniaCommunity-acquired Pneumonia; Pneumoniacompleted370
2025-03-20P3Merck Sharp & Dohme LLC MRKNCT03867084 Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Hepatocellular Carcinomacompleted959
2025-03-20P3AstraZeneca AZNNCT04609904 Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)Asthmacompleted2187
2025-03-20P3Liquidia Technologies, Inc. LQDANCT04691154 A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILDPulmonary Arterial Hypertension; Pulmonary Hypertension Due to Lung Diseasesactive not recruiting28
2025-03-20P3argenx ARGXNCT05681481 A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous PemphigoidBullous Pemphigoidterminated64
2025-03-20P1/P2Innovent Biologics (Suzhou) Co. Ltd.NCT05774873 The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2Advanced Solid Tumorscompleted28
2025-03-20P2Carrick Therapeutics LimitedNCT05963984 A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult ParticipantsMetastatic Breast Cancer; Locally Advanced Breast Cancer; Breast Cancercompleted60
2025-03-20P1/P2Staidson (Beijing) Biopharmaceuticals Co., LtdNCT06038916 To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndromecompleted47
2025-03-20P2Merck Sharp & Dohme LLC MRKNCT06113328 A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)Non-segmental Vitiligoterminated169
2025-03-21P2Bristol-Myers Squibb BMYNCT03920267 Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus ErythematosusSystemic Lupus Erythematosuscompleted261
2025-03-21P3AstraZeneca AZNNCT04609878 Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)Asthmacompleted2274
2025-03-21P3EMD Serono Research & Development Institute, Inc.NCT05061823 Bintrafusp Alfa Program Rollover StudyLung Cancer; Cancercompleted22
2025-03-21P3Spine BioPharma, IncNCT05516992 Moderate - Severe Degenerative Disc Disease Evaluation of the Lumbar SpineLumbar Degenerative Disc Diseaseactive not recruiting417
2025-03-21P3Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.NCT06209320 A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye DropsMyopiaactive not recruiting777
2025-03-21P3Alcon Research ALCNCT06544694 A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye DiseaseDry Eye Diseasecompleted80
2025-03-22P1/P2Xilio Development, Inc. XLONCT05052268 XTX202 in Patients With Advanced Solid TumorsAdvanced Solid Tumorcompleted95
2025-03-22P1/P2Lubris Bio Pty LtdNCT06495307 RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)Ocular Graft-versus-host Diseaseterminated3
2025-03-23P3Eurofarma Laboratorios S.A.NCT05214911 Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in ChildrenAllergic Rhinitiscompleted262
2025-03-23P1/P2Altesa Biosciences, Inc.NCT06834295 A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]VapendavirHealthy Malescompleted8
2025-03-24P2/P3Gilead Sciences GILDNCT02881320 Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1HIV-1 Infectionactive not recruiting177
2025-03-24P3BioTissue Holdings, IncNCT04450693 Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)Diabetic Foot Infection; Non-healing Wound; Non-healing Diabetic Foot Ulcercompleted106
2025-03-24P3AstraZeneca AZNNCT05398263 Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent AsthmaAsthmaterminated125
2025-03-24P2Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)NCT05558696 A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)Polycythemia Veracompleted20
2025-03-24P2Biohaven Therapeutics Ltd. BHVNNCT06603623 Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of MigraineMigrainecompleted647
2025-03-25P2Sarfez Pharmaceuticals, Inc.NCT06176794 Immediate Release Torsemide Versus Extended Release Torsemide After Salty MealHeart Failurewithdrawn
2025-03-25P2EnliTISA (Shanghai) Pharmaceutical Co., Ltd.NCT07319351 Safety and Preliminary Efficacy of TISA-818 Injection in Patients With Acute Respiratory Distress SyndromeAcute Respiratory Distress Syndrome (ARDS)completed57
2025-03-25P1/P2BioNanoSim Ltd.NCT07869953 Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior UveitisNon-Infectious Anterior Uveitiscompleted18
2025-03-26P2Agenus Inc. AGENNCT03894215 RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerCervical Cancerterminated211
2025-03-26P3Sun Pharmaceutical Industries LimitedNCT04314544 Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)Active Psoriatic Arthritiscompleted508
2025-03-26P2Alexion Pharmaceuticals, Inc.NCT04564339 Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)Lupus Nephritis; Immunoglobulin A Nephropathyterminated123
2025-03-26P2Novartis Pharmaceuticals NVSNCT05524051 A Multi-center Study to Evaluate the Safety, Tolerability and Efficacy of TIN816 in Patients at Risk for Acute Kidney Injury Following Cardiac Surgery.Acute Kidney Injury Following Cardiac Surgeryterminated102
2025-03-26P3Amgen AMGNNCT05907122 A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected MelanomaMelanomacompleted256
2025-03-26P2Apollo Therapeutics Ltd APONCT06436183 A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic DermatitisAtopic Dermatitis; Atopic; Dermatitis; Dermatologic Disease; Eczema; Eczema Atopic Dermatitis; Eczemcompleted62
2025-03-27P2Insmed Incorporated INSMNCT05147805 A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionPulmonary Arterial Hypertensioncompleted102
2025-03-27P2GCP-Service International West GmbHNCT05583552 Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based TherapyMyelodysplastic Syndromes; Acute Myeloid Leukemiacompleted46
2025-03-27P3Addpharma Inc.NCT06052748 A Study to Evaluate the Efficacy and Safety of AD-223Hypertension,Essentialcompleted502
2025-03-27P3Laboratorios LiomontNCT07549386 Efficacy and Safety of Etoricoxib+Diacerein in Osteoarthritis.Pain Management; Osteoarthritiscompleted123
2025-03-28P2Theriva Biologics SL TOVXNCT05673811 Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic CancerPancreatic Adenocarcinoma; Metastaticcompleted112
2025-03-28P2Beckley Psytech LimitedNCT05870540 BPL-003 Efficacy and Safety in Treatment Resistant DepressionTreatment Resistant Depressioncompleted196
2025-03-28P2Ascendis Pharma A/S ASNDNCT05980598 TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell CarcinomaHead and Neck Neoplasmsterminated27
2025-03-28P2Amgen AMGNNCT06502977 Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of TreatmentExtensive Stage Small Cell Lung Canceractive not recruiting32
2025-03-28P3Yuhan CorporationNCT06625931 Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral NutritionParenteral Nutritioncompleted60
2025-03-28P3SPH-BIOCAD (HK) LimitedNCT07008547 To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque PsoriasisPlaque Psoriasiscompleted202
2025-03-30P1/P2Vascudyne, Inc.NCT05567757 Initial Safety Study of the TRUE AVC in Hemodialysis Access (TRUE AVC I Study)End Stage Renal Diseasecompleted11
2025-03-30P2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06089278 A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.Sinusitiscompleted160
2025-03-30P2Altesa Biosciences, Inc.NCT06149494 RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory InfectionCOPD Exacerbation Acute; COPD With Acute Lower Respiratory Infection; Rhinovirus; Virus Diseases; Vicompleted52
2025-03-30 est.P2Keymed Biosciences Co.LtdNCT06171074 Study of CM310 in Subjects With Seasonal Allergic RhinitisSeasonal Allergic Rhinitisunknown100
2025-03-30 est.P2Jubaan Ltd.NCT06612281 Evaluation of Gixam's Performance in a FIT Negative PopulationColorectal Adenoma; Colorectal Cancer (CRC); Colorectal Cancer (CRC) Screeningrecruiting400
2025-03-31P2Astellas Pharma Global Development, Inc.NCT03364153 Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)Stargardt's Macular Dystrophycompleted121
2025-03-31P2Regeneron Pharmaceuticals REGNNCT03916627 Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsNon-small Cell Lung Cancer; Hepatocellular Carcinoma; Head and Neck Squamous Cell Carcinomaactive not recruiting65
2025-03-31P2Leap Therapeutics, Inc.NCT04363801 A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal CancerGastric Cancer; Gastric Adenocarcinoma; GastroEsophageal Cancerterminated247
2025-03-31P2Mirror Biologics, Inc.NCT04444622 Immunotherapy for Third Line Metastatic Colorectal CancerMetastatic Colorectal Cancercompleted29
2025-03-31 est.P3AllerdermNCT04500834 Metal Panel Allergen Patch Test StudyAtopic Dermatitis Eczemaunknown200
2025-03-31 est.P3Zogenix MDS, Inc.NCT04581733 A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)Thymidine Kinase 2 Deficiencywithdrawn
2025-03-31P2Dompé Farmaceutici S.p.ANCT04628481 A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell FunctionRecent Onset type1 Diabetesterminated289
2025-03-31P1/P2MegaPro Biomedical Co. Ltd.NCT04643418 Phase 1/2a Study of MPB-1734 in Patients With Advanced Solid TumorsSolid Tumor, Unspecified, Adultrecruiting81
2025-03-31P3Opthea Limited CKDXFNCT04757610 OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)Neovascular Age-related Macular Degenerationterminated986
2025-03-31P3Opthea Limited CKDXFNCT04757636 OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)Neovascular Age-related Macular Degenerationterminated998
2025-03-31P2BeiGeneNCT05068440 Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor ZanubrutinibRelapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-cell Lymphomacompleted65
2025-03-31P2GlaxoSmithKlineNCT05082285 A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy InfantsInfections, Meningococcalcompleted726
2025-03-31P3Corcept Therapeutics CORTNCT05257408 Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube CancerOvarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasmsactive not recruiting381
2025-03-31 est.P1/P2Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT05435248 Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)Advanced or Metastatic NSCLCunknown354
2025-03-31P2HighTide Therapeutics (Hong Kong) LimitedNCT05623189 HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-DiabetesNonalcoholic Steatohepatitis (NASH); Type 2 Diabetescompleted218
2025-03-31P2AbbVie ABBVNCT05941442 A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic DisorderPanic Disorderterminated80
2025-03-31P2UCB Biopharma SRLNCT06055985 A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's DiseaseParkinson Diseasecompleted207
2025-03-31P2ShionogiNCT06086626 A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and InfantsGram-Negative Bacterial Infectionscompleted30
2025-03-31P3Dermata Therapeutics DRMANCT06090721 DMT310-009 Topical in the Treatment of Acne VulgarisAcne Vulgariscompleted520
2025-03-31 est.P2Evon Medics LLCNCT06434818 Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use DisordersSubstance Use Disorders; Opioid Use Disorder; Alcohol Use Disorder; Cocaine Use Disorder; Methamphetunknown300
2025-03-31P2Dizal PharmaceuticalsNCT06511869 AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)Peripheral T-cell Lymphomacompleted48
2025-03-31 est.P2Acousia Therapeutics GmbHNCT06521190 ACOU085 for Hearing Loss Prevention in Testicular Cancer Patients Receiving CisplatinCisplatin-induced Hearing Lossunknown40
2025-03-31 est.P2Genrix (Shanghai) Biopharmaceutical Co., Ltd.NCT06642961 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate toAsthmaunknown150
2025-03-31 est.P2Hyundai PharmNCT06647550 To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and ExerciseType 2 Diabetes Mellitus (T2DM)recruiting160

← 2025-02 | 2025-04 →

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.